A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/s0090-8258(03)00007-6 ◽

2003 ◽

Vol 89 (1) ◽

pp. 95-98 ◽

Author(s):

Mark A Hoffman ◽

John A Blessing ◽

Samuel S Lentz

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Sensitive ◽

Download Full-text

A Phase II Trial of CI-958 in Recurrent Platinum-Sensitive Ovarian Carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.2001.6182 ◽

2001 ◽

Vol 81 (3) ◽

pp. 433-435 ◽

Author(s):

Mark A. Hoffman ◽

John A. Blessing ◽

Evelyn R. Nuñez

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Sensitive

Download Full-text

Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.2001.6441 ◽

2002 ◽

Vol 84 (1) ◽

pp. 32-35 ◽

Author(s):

Steven C. Plaxe ◽

John A. Blessing ◽

Michael A. Bookman ◽

William T. Creasman

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Sensitive

Download Full-text

Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma—a Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/s0090-8258(03)00068-4 ◽

2003 ◽

Vol 89 (1) ◽

pp. 148-154 ◽

Author(s):

Jeffrey D Bloss ◽

Mark F Brady ◽

Shu Yuan Liao ◽

Thomas Rocereto ◽

Edward E Partridge ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Papillary Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Serous Ovarian Carcinoma ◽

Serous Papillary Carcinoma

Download Full-text

A Phase II Trial of Gallium Nitrate (NSC #15200) in Previously Treated Ovarian Carcinoma A Gynecologic Oncology Group Study

American Journal of Clinical Oncology ◽

10.1097/00000421-199108000-00015 ◽

1991 ◽

Vol 14 (4) ◽

pp. 349-351 ◽

Author(s):

John H. Malfetano ◽

John A. Blessing ◽

Mark D. Adelson

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gallium Nitrate ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Previously Treated

Download Full-text

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70331-2 ◽

2007 ◽

Vol 2007 ◽

pp. 82-83

Author(s):

J.T. Thigpen

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Faculty Opinions recommendation of Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969752.793471344 ◽

2013 ◽

Author(s):

David Kushner ◽

Ryan Spencer

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (A Gynecologic Oncology Group Study)

American Journal of Obstetrics and Gynecology ◽

10.1016/0002-9378(89)90507-3 ◽

1989 ◽

Vol 161 (2) ◽

pp. 309-312 ◽

Author(s):

Gregory P. Sutton ◽

John A. Blessing ◽

Neil Rosenshein ◽

Guy Photopulos ◽

Philip J. DiSaia

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

A phase II trial of trebaninib (AMG 386), a selective angiopoietin 1/2 neuralizing peptibody in patients with persistent/recurrent carcinoma of the endometrium: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.055 ◽

2015 ◽

Vol 137 ◽

pp. 24 ◽

Author(s):

K.N. Moore ◽

M. Sill ◽

M.E. Tenney ◽

C.J. Darus ◽

D. Griffin ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Recurrent Carcinoma ◽

Amg 386 ◽

Download Full-text

A phase II trial of didemnin B (NSC No. 325319) in advanced and recurrent cervical carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/0090-8258(92)90055-n ◽

1992 ◽

Vol 44 (3) ◽

pp. 268-270 ◽

Author(s):

Allan J. Jacobs ◽

John A. Blessing ◽

Alan Munoz

Keyword(s):

Cervical Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

Yearbook of Oncology ◽

10.1016/s1040-1741(10)79511-7 ◽

2010 ◽

Vol 2010 ◽

pp. 73-74

Author(s):

J.T. Thigpen

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Her2 Positive ◽

Oncology Group Study

Download Full-text